Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Sees Significant Increase in Short Interest

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) saw a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 298,780 shares, an increase of 528.9% from the May 14th total of 47,507 shares. Based on an average daily volume of 667,164 shares, the short-interest ratio is presently 0.4 days. Approximately 0.0% of the shares of the company are short sold.

Daiichi Sankyo Price Performance

OTCMKTS DSNKY opened at $15.93 on Wednesday. The stock has a 50-day simple moving average of $17.03 and a 200 day simple moving average of $19.25. Daiichi Sankyo has a twelve month low of $14.98 and a twelve month high of $27.50. The stock has a market capitalization of $30.18 billion, a PE ratio of 16.95, a P/E/G ratio of 1.11 and a beta of -0.16. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.69.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its earnings results on Monday, May 11th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.74%. The business had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.74 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. Research analysts anticipate that Daiichi Sankyo will post 0.94 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 5th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Daiichi Sankyo presently has an average rating of “Hold”.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.